Jun 10, 2018
Research Presented at ASM Microbe 2018: TGV-MYC for the Treatment of Vulvovaginal Candidiasis: Results from A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial
Want create site? Find Free WordPress Themes and plugins.

Mycobactovir for the Treatment of Vulvovaginal Candidiasis: Results from A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial (ex-US)

TGV-Laboratories to Present  Results from  Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial. Research Presented in a Poster Session at American Society for Microbiology (ASM) Microbe 2018

 

NEW YORK, NY, June 10, 2018 — TGV-Therapeutics  (TGV), a  privately held company and our goal is to bring the therapy of invasive fungal infections to a principally new level of the efficacy. The study, coordinated by Drs. V. Tetz and G. Tetz, was presented by Dr. G. Tetz in a poster session at American Society for Microbiology (ASM) Microbe 2018, June 7–11, 2018, in Atlanta

Background: Vulvovaginal candidiasis (VVC) is a common vaginal infection affecting about 75% of women during their lifetime. The primary causative agents of VVC are Candida albicans and C. glabrata, which has emerged as the most common non-albicans Candida species. Approximately 3-12% of Candida spp. are resistant to azoles, which can result in treatment failure, recurrent VVC, and increased transmission of resistant strains. TGV-MYC is a first-in-class, orally available, small molecule inhibitor of fungal nucleic acid synthesis and chitin synthase. In vitro, TGV-MYC exerted a significant fungicidal effect against azole- and echinocandin-resistant Candida spp. isolates. Methods: A multicenter, randomized, double-blind, placebo-controlled trial on the efficacy and safety of TGV-MYC in patients with acute exacerbation of chronic VVC was conducted in Europe. Subjects received TGV-MYC capsules (1200 mg BID) or placebo for 6 days (p<0.001). The primary endpoint was clinical cure (based on gynecological examination [itching, burning, dysuria, and discharge]) and mycological response at day 7. The patients had follow-up visits at 7 days after the last therapeutic dose (14th day). Results: There was a statistically significant difference between the TGV-MYC and placebo arms to both clinical and mycological cure rates. The clinical cure rates were 92.6% (88/95) at day 7 and 95.8% (91/95) at day 14 in the  TGV-MYC group, and were 36.2% (34/94) at day 7 and 71.3% (67/94) at day 14 in the placebo group. The mycological cure rates in the TGV-MYC and placebo groups were 83.2% (79/95) and 58.5% (55/94), respectively, at follow-up on day 7 (P <0.001 for all). No serious adverse events were associated with TGV-MYC treatment.Conclusions: This study demonstrates that TGV-MYC (1200 mg orally BID for 6 days) is highly efficacious treatment for VVC. TGV-MYC was well tolerated and had a benign safety profile with no serious adverse events detected. Overall, this drug has a promising therapeutic potential, especially in cases caused by azole- and echinocandin-resistant strains.

 

Contact:

George Tetz

646-617-3088

tetstgvlabs.com

Did you find apk for android? You can find new Free Android Games and apps.
Mar 07, 2018
Want create site? Find Free WordPress Themes and plugins.

NEW YORK, NY / ACCESSWIRE / March 7, 2018 / TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced today it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.

Did you find apk for android? You can find new Free Android Games and apps.
Mar 10, 2018
Want create site? Find Free WordPress Themes and plugins.

DANIEL JENNING’S BLOG

SEEKING ALPHA

Summary

  • Data indicates that the antibiotic MYC-053; developed by TGV Therapeutics, has proven effective against the deadly fungal infection Candida auris (C.auris) candidemia.
  • Initial testing by TGV was so promising the NIH decided to expand research into MYC-053.
  • C.auris is a pathogenic fungus that has been known to spread in healthcare facilities. C.auris can infect wounds, the bloodstream, and the urinary tract.
  • The pathogen is extremely dangerous because itis resistant to many existing antifungal drugs.
  • MYC-053 is TGV’s lead product candidate, and itis described as a “novel antifungal agent that is structurally distinct fromthe three main classes of antifungal antibiotics.”.
Did you find apk for android? You can find new Free Android Games and apps.